8EZM

Pfs25 in complex with transmission-reducing antibody AS01-63

8EZM の概要

• エントリーDOI: 10.2210/pdb8ezm/pdb
• 分子名称: 25 kDa ookinete surface antigen, Transmission-reducing antibody AS01-63, Single-chain Fv, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
• 機能のキーワード: pfs25, transmission-blocking vaccine, immune system
• 由来する生物種: Plasmodium falciparum (malaria parasite P. falciparum); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 48542.44

構造登録者

Shukla, N.,Tang, W.K.,Tolia, N.H. (登録日: 2022-11-01, 公開日: 2023-08-16, 最終更新日: 2024-10-23)

主引用文献

Shukla, N.,Tang, W.K.,Coelho, C.H.,Long, C.A.,Healy, S.A.,Sagara, I.,Miura, K.,Duffy, P.E.,Tolia, N.H.
A human antibody epitope map of the malaria vaccine antigen Pfs25.
Npj Vaccines, 8:108-108, 2023

PubMed Abstract: Pfs25 is a leading antigen for a malaria transmission-blocking vaccine and shows moderate transmission-blocking activity and induction of rapidly decreasing antibody titers in clinical trials. A comprehensive definition of all transmission-reducing epitopes of Pfs25 will inform structure-guided design to enhance Pfs25-based vaccines, leading to potent transmission-blocking activity. Here, we compiled a detailed human antibody epitope map comprising epitope binning data and structures of multiple human monoclonal antibodies, including three new crystal structures of Pfs25 in complex with transmission-reducing antibodies from Malian volunteers immunized with Pfs25 conjugated to EPA and adjuvanted with AS01. These structures revealed additional epitopes in Pfs25 capable of reducing transmission and expanded this characterization to malaria-exposed humans. This work informs immunogen design to focus the antibody response to transmission-reducing epitopes of Pfs25, enabling development of more potent transmission-blocking vaccines for malaria.

PubMed: 37542029
DOI: 10.1038/s41541-023-00712-z

実験手法

X-RAY DIFFRACTION (2.1 Å)